ST未名：重组人神经生长因子SMR001滴眼液III期临床试验伦理批件获批

Core Viewpoint - The announcement highlights that ST Unimed's wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., has received ethical approval for its innovative drug SMR001 eye drops, aimed at treating moderate to severe dry eye disease, allowing the commencement of Phase III clinical trials [1] Group 1 - The innovative drug SMR001 is a recombinant human nerve growth factor [1] - The ethical approval was granted by the Ethics Committee of Beijing Tongren Hospital, affiliated with Capital Medical University [1] - The Phase III key registration clinical trial is now officially set to begin [1]